SEC Tracker
Get the app

Allarity Therapeutics ALLR

Allarity Therapeutics terminated equity line of credit offering

Securities offering

Form
424B5
Filed
Importance
Routine
  1. Terminated Purchase Agreement with Tumim on October 28, 2026
  2. Primary offering of up to $6,000,000 of common stock ended
  3. Resale coverage for previously issued shares remains valid

Written from the 424B5 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Allarity Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
  2. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  3. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  4. Pluri PLUR public float $15M, Dec 31, 2025
  5. Edesa Biotech EDSA public float $14M, Mar 31, 2025, over 18 months old